Olodanrigan

Olodanrigan (EMA401) is a highly selective, orally active, peripherally restricted angiotensin II type 2 receptor (AT2R) antagonist. It is under development as a neuropathic pain therapeutic agent. Olodanrigan (EMA401) analgesic action appears to involve inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons[1][2][3][4].

Product Specifications

CAS Number

[1316755-16-4]

Product Name Alternative

EMA401; PD-126055; (S) -EMA400

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Angiotensin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease; Endocrinology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/EMA401.html

Purity

98.89

Solubility

DMSO : 200 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL

Smiles

O=C([C@H]1N(C(C(C2=CC=CC=C2)C3=CC=CC=C3)=O)CC4=C(C(OCC5=CC=CC=C5)=C(OC)C=C4)C1)O

Molecular Formula

C32H29NO5

Molecular Weight

507.58

Precautions

H302, H315, H319, H335

References & Citations

[1]Anand U et al. Mechanisms underlying clinical efficacy of Angiotensin II type 2 receptor (AT2R) antagonist EMA401 in neuropathic pain: clinical tissue and in vitro studies. Mol Pain. 2015 Jun 26;11:38.|[2]Suguru Koyama, et al. An Electroencephalography Bioassay for Preclinical Testing of Analgesic Efficacy.|[3]Rice AS et al. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet. 2014 May 10;383 (9929) :1637-47.